指南与共识胃肠动力与功能性疾病消化道肿瘤与早癌

美国胃肠病学会临床实践更新:过度活动型埃勒斯-当洛斯综合征的胃肠表现及自主神经或免疫功能障碍专家综述

AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review.
指南 / 共识 · Clin Gastroenterol Hepatol · 2025-05-19

美国胃肠病学会发布专家综述,阐述过度活动型埃勒斯-当洛斯综合征(hEDS)或过度活动谱系障碍(HSDs)合并体位性心动过速综合征(POTS)和/或肥大细胞活化综合征(MCAS)患者的胃肠表现评估与管理原则,提出16条最佳实践建议,涉及筛查、诊断检测与治疗策略。

要点

  • 对hEDS/HSDs患者应询问关节过度活动,可考虑用Beighton评分筛查,阳性者考虑2017年诊断标准或转诊专科。
  • POTS/MCAS检测应针对有相应临床表现者,不支持对所有hEDS/HSDs患者普遍检测。
  • 胃肠症状管理应针对最突出症状和异常功能检测结果,并兼顾POTS/MCAS治疗。

核心结论

  • hEDS/HSDs与POTS和/或MCAS存在观察性关联且胃肠表现重叠,但解释其关系的生物学机制实验证据有限且仍在演变。
  • 胃肠症状评估应遵循DGBI的通用方法,检测应针对有相应临床表现者,不支持对所有hEDS/HSDs患者普遍检测POTS/MCAS。

研究设计与样本

  • 美国胃肠病学会(AGA)研究所临床实践更新委员会和AGA理事会委托并批准的专家综述,经内部同行评审和《Clinical Gastroenterology and Hepatology》标准外部同行评审。
  • 最佳实践建议来自已发表文献综述和专家意见,未进行系统评价,因此不建议对证据质量或推荐强度进行正式评级。

主要发现

  • hEDS/HSDs与POTS和/或MCAS存在观察性关联,胃肠表现重叠,但解释关系的生物学机制实验证据有限且仍在演变。
  • hEDS/HSDs人群盆底功能障碍尤其是直肠低敏感高发,下消化道症状如排空不全可考虑肛门直肠测压、球囊排出试验或排粪造影。
  • hEDS/HSDs合并POTS者慢性上消化道症状中,胃排空异常可能比一般人群更常见,排除解剖结构疾病后可考虑胃运动功能检测。

关键数值与推荐

  • 建议1:临床医生应知晓hEDS/HSDs与POTS和/或MCAS的观察性关联及重叠胃肠表现,实验证据有限且演变中。
  • 建议2:POTS/MCAS检测应针对有临床表现者,当前证据不支持对所有hEDS/HSDs患者普遍检测。
  • 建议3:胃肠科医生应询问关节过度活动并强烈考虑将Beighton评分作为筛查工具;筛查阳性可考虑应用2017年诊断标准诊断hEDS或转诊专科。
  • 建议6:怀疑MCAS时,可考虑基线及症状发作后1-4小时血清类胰蛋白酶检测,较基线升高20%加2 ng/mL为肥大细胞活化证据。
  • 建议10:hEDS/HSDs伴下消化道症状如排空不全者,鉴于盆底功能障碍尤其是直肠低敏感高发,应考虑肛门直肠测压、球囊排出试验或排粪造影。

临床怎么用

  • 对hEDS/HSDs患者应询问关节过度活动并考虑Beighton评分筛查,阳性者考虑2017年诊断标准或转诊专科。
  • POTS可通过体位生命体征检测(如站立10分钟内症状性心率增加30次/分或以上且无直立性低血压),难治性胃肠症状伴直立不耐受者可考虑转诊心脏或神经专科自主神经检测。
  • 怀疑MCAS时可考虑基线及症状发作后1-4小时血清类胰蛋白酶检测,诊断支持者转诊过敏专科或肥大细胞疾病研究中心。
  • 胃肠症状管理应针对最突出症状和异常功能检测结果,兼顾POTS和/或MCAS治疗;POTS治疗可包括增加液体和盐摄入、运动训练、弹力袜。
  • 怀疑MCAS者可受益于组胺受体拮抗剂和/或肥大细胞稳定剂,并避免触发因素如某些食物、酒精、强烈气味、温度变化、机械刺激、情绪困扰、花粉、霉菌或特定药物。

局限性

  • 未进行系统评价,最佳实践建议不附带证据质量或推荐强度的正式评级。
  • 解释hEDS/HSDs与POTS和/或MCAS关系的生物学机制实验证据有限且仍在演变。
  • 当前数据不支持对所有无原发或继发肥大细胞疾病临床或实验室证据的hEDS/HSDs患者常规评估胃肠症状时使用肥大细胞检测。
  • 支持对hEDS/HSDs中双糖酶缺乏或其他饮食介导机制作为胃肠症状常规检测的研究不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

DESCRIPTION: The purpose of this Clinical Practice Update Expert Review is to describe key principles in the evaluation and management of patients with disorders of gut-brain interaction (DGBI) and hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorders (HSDs) with coexisting postural orthostatic tachycardia syndrome (POTS) and/or mast cell activation syndrome (MCAS). METHODS: This expert review was commissioned and approved by the American Gastroenterological Association (AGA) Institute Clinical Practice Updates Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the Clinical Practice Updates Committee and external peer review through standard procedures of Clinical Gastroenterology and Hepatology. These Best Practice Advice statements were drawn from a review of the published literature and from expert opinion. Because systematic reviews were not performed, these Best Practice Advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. BEST PRACTICE ADVICE 1: Clinicians should be aware of the observed associations between hEDS or HSDs and POTS and/or MCAS and their overlapping gastrointestinal (GI) manifestations; while theoretical explanations exist, experimental evidence of the biological mechanisms that explain relationships is limited and evolving. BEST PRACTICE ADVICE 2: Testing for POTS/MCAS should be targeted to patients presenting with clinical manifestations of POTS/MCAS, but universal testing for POTS/MCAS in all patients with hEDS/HSDs is not supported by the current evidence. BEST PRACTICE ADVICE 3: Gastroenterologists seeing patients with DGBI should inquire about joint hypermobility and strongly consider incorporating the Beighton score for assessing joint hypermobility into their practice as a screening tool; if the screen is positive, gastroenterologists may consider applying 2017 diagnostic criteria to diagnose hEDS (https://www.ehlers-danlos.com/wp-content/uploads/2017/05/hEDS-Dx-Criteria-checklist-1.pdf) or offer appropriate referral to a specialist where resources are available. BEST PRACTICE ADVICE 4: Testing for POTS through postural vital signs (eg, symptomatic increase in heart rate of 30 beats/min or more with 10 minutes of standing during an active stand or head-up tilt table test in the absence of orthostasis) and referral to specialty practices (eg, cardiology or neurology) for autonomic testing should be considered in patients with hEDS/HSDs and refractory GI symptoms who also report orthostatic intolerance after exclusion of medication side effects and appropriate lifestyle or behavioral modifications (eg, adequate hydration and physical exercise) have been attempted but is not required for all patients with hEDS/HSDs who report GI symptoms alone. BEST PRACTICE ADVICE 5: In patients presenting to gastroenterology providers, testing for mast cell disorders including MCAS should be considered in patients with hEDS/HSDs and DGBI who also present with episodic symptoms that suggest a more generalized mast cell disorder (eg, visceral and somatic pain, pruritus, flushing, sweating, urticaria, angioedema, wheezing, tachycardia, abdominal cramping, vomiting, nausea, diarrhea, urogynecological and neurological complaints) involving 2 or more physiological systems (eg, cutaneous, GI, cardiac, respiratory, and neuropsychiatric), but current data do not support the use of these tests for routine evaluation of GI symptoms in all patients with hEDS/HSDs without clinical or laboratory evidence of a primary or secondary mast cell disorder. BEST PRACTICE ADVICE 6: If MCAS is suspected, diagnostic testing with serum tryptase levels collected at baseline and 1-4 hours following symptom flares may be considered by the gastroenterologist; increases of 20% above baseline plus 2 ng/mL are necessary to demonstrate evidence of mast cell activation. BEST PRACTICE ADVICE 7: If a diagnosis of MCAS is supported through clinical and/or laboratory features, patients should be referred to an allergy specialist or mast cell disease research center where additional testing (eg, urinary N-methylhistamine, leukotriene E4, 11β-prostaglandin F2) may be performed. BEST PRACTICE ADVICE 8: Diagnostic evaluation of GI symptoms consistent with DGBI in patients with hEDS/HSDs and comorbid POTS and/or MCAS should follow a similar approach to the evaluation of DGBI as in the general population including the use of a positive symptom-based diagnostic strategy and limited noninvasive testing. BEST PRACTICE ADVICE 9: Testing for celiac disease may be considered earlier in the diagnostic evaluation of patients with hEDS/HSDs who report a variety of GI symptoms and not only limited to those with diarrhea. There is insufficient research to support routine testing for disaccharidase deficiencies or other diet-mediated mechanisms as causes of GI symptoms in hEDS/HSDs. BEST PRACTICE ADVICE 10: Diagnostic testing for functional defecation disorders with anorectal manometry, balloon expulsion test, or defecography should be considered in patients with hEDS/HSDs and lower GI symptoms such as incomplete evacuation given the high prevalence of pelvic floor dysfunction, especially rectal hyposensitivity, in this population. BEST PRACTICE ADVICE 11: In patients with hEDS/HSDs and comorbid POTS who report chronic upper GI symptoms, timely diagnostic testing of gastric motor functions (eg, measurement of gastric emptying and/or accommodation) should be considered after appropriate exclusion of anatomical and structural diseases, as abnormal gastric emptying may be more common than in the general population. BEST PRACTICE ADVICE 12: Medical management of GI symptoms in hEDS/HSDs and POTS/MCAS should focus on treating the most prominent GI symptoms and abnormal GI function test results. In addition to general DGBIs and GI motility disorder treatment, management should also include treating any symptoms attributable to POTS and/or MCAS. BEST PRACTICE ADVICE 13: Treatment of POTS may include increasing fluid and salt intake, exercise training, and use of compression garments. Special pharmacological treatments for volume expansion, heart rate control, and vasoconstriction with integrated care from multiple specialties (eg, cardiology, neurology) should be considered in patients who do not respond to conservative lifestyle measures. BEST PRACTICE ADVICE 14: When MCAS is suspected, patients can benefit from treatment with histamine receptor antagonists and/or mast cell stabilizers, in addition to avoiding triggers such as certain foods, alcohol, strong smells, temperature changes, mechanical stimuli (eg, friction), emotional distress (eg, pollen, mold), or specific medications (eg, opioids, nonsteroidal anti-inflammatory agents, iodinated contrast). BEST PRACTICE ADVICE 15: Besides general nutritional support, special diets including a gastroparesis diet (ie, small particle diet) and various elimination diets (eg, low fermentable carbohydrates, gluten- or dairy-free, low-histamine diets) can be considered for improving GI symptoms. Dietary interventions should be delivered with appropriate nutritional counseling or guidance to avoid the pitfalls of restrictive eating. BEST PRACTICE ADVICE 16: Management of chronic GI symptoms in patients with hEDS/HSDs who do not exhibit symptoms consistent with POTS or MCAS should align with existing approaches to management of DGBI and GI motility disorders in the general population, including integrated multidisciplinary care involving multiple specialties, where appropriate (eg, cardiology, rheumatology, dietician, psychology).

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Aziz Q, Harris LA, Goodman BP, et al. AGA Clinical Practice Update on GI Manifestations and Autonomic or Immune Dysfunction in Hypermobile Ehlers-Danlos Syndrome: Expert Review. Clin Gastroenterol Hepatol. 2025. PMID: 40387691. doi:10.1016/j.cgh.2025.02.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。